Neuland Laboratories (NSE:NEULANDLAB) GF Value Rank: 5 (As of Jul. 13, 2026) — 25% Above Median


NSE:NEULANDLAB Neuland Laboratories Ltd NSE:NEULANDLAB
92 GF Score
Price ₹19,506.00
GF Value ₹16,053.42
Valuation Modestly Overvalued
! 3 Warning Signs
View Full Analysis

What is Neuland Laboratories GF Value Rank?

Neuland Laboratories NSE:NEULANDLAB -0.18% 92 GF Value Rank is 5 as of Jul. 13, 2026, which is 25% above its 10-year median of 4.00. GuruFocus rates NSE:NEULANDLAB with a GF Score™ of 92/100 and a GF Value™ of ₹16,053.42 (Modestly Overvalued). The stock has 3 warning signs investors should review.

Neuland Laboratories has the GF Value Rank of 5.

GF Value Rank evaluates the exclusive GuruFocus valuation and performance of a stock, rated on a scale from 1 to 10. It is determined by the price-to-GF-Value (P/GF Value) ratio, a proprietary metric calculated based on historical multiples along with an adjustment factor based on a company's past returns and growth and future estimates of the business' performance.

GuruFocus found that for valuation, we cannot simply give stocks a better GF Value rank simply because they have a lower P/GF Value ratio. Backtesting shows that over the long term, the two worst-performing groups are the most expensive group (with the highest P/GF Value ratio) and the least expensive group (with the lowest P/GF Value ratio).

We can understand why the most expensive group underperforms. We were initially puzzled by the underperformance of the least expensive group, but we realized there is a reason why some stocks are super cheap. If they look too undervalued, it is often because the businesses behind them are poor quality. The market realized this and gave them low valuations. In a way, the market is efficient.

After multiple backtesting analyses, we granted the stocks in third-cheapest percentile the highest GF Value rank, as they have performed the best over a full market cycle. Stock performance is actually not as sensitive to valuation as it is to growth and profitability. On average, the companies in the 20%-50% valuation groups have similar performances. Therefore, we should avoid the most expensive and the least expensive stocks. We can be more tolerant of valuation.

A higher score indicates a stock with a relatively low valuation and substantial potential for outperformance. Conversely, a lower score often reflects stocks that are either highly overvalued or deeply undervalued, both of which tend to underperform.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.


Neuland Laboratories GF Value Rank Related Terms


NSE:NEULANDLAB vs ZTS, UTHR: GF Value Rank Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Neuland Laboratories's GF Value Rank, along with its competitors' market caps and GF Value Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Neuland Laboratories GF Value Rank vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Neuland Laboratories's GF Value Rank distribution charts can be found below:

* The bar in red indicates where Neuland Laboratories's GF Value Rank falls into.


NSE:NEULANDLAB
92GF Score
Neuland Laboratories Ltd NSE:NEULANDLAB
GF Value Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about GF Value Rank →
What does a GF Value Rank of 5 mean?
Neuland Laboratories (NSE:NEULANDLAB) has a GF Value Rank of 5 as of Jul. 13, 2026. GF Value Rank is given based on historical multiples along with past returns, growth and future estimates of the business' performance. View historical data on Neuland Laboratories and its competitors. This is 25% above median its historical median of 4.00. Over the past decade, Neuland Laboratories' GF Value Rank has ranged from 1.00 to 10.00.
Is Neuland Laboratories' GF Value Rank too high?
Neuland Laboratories' current GF Value Rank of 5 is 25% above median its 10-year median of 4.00. Over the past 10 years, this metric has ranged from a low of 1.00 to a high of 10.00. Overall, Neuland Laboratories has a GF Score™ of 92/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Neuland Laboratories' GF Value Rank compare to ZTS and UTHR?
Neuland Laboratories' GF Value Rank of 5 can be compared against companies in the Drug Manufacturers industry. Historically, Neuland Laboratories' own GF Value Rank has ranged from 1.00 to 10.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Value Rank for a Drug Manufacturers company?
A good GF Value Rank depends on the Drug Manufacturers industry context. However, GF Value Rank should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Value Rank mean?
A high GF Value Rank can signal that a stock is expensive relative to its fundamentals. GF Value Rank is given based on historical multiples along with past returns, growth and future estimates of the business' performance. View historical data on Neuland Laboratories and its competitors. Neuland Laboratories's current GF Value Rank is 5, which is 25% above median its own 10-year median of 4.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neuland Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Neuland Laboratories (NSE:NEULANDLAB) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹16,053.42, compared to a current price of ₹19,506.00 — trading 21.5% above its estimated fair value. The current GF Value Rank is 5, which is 25% above median its 10-year median of 4.00. Neuland Laboratories' overall GF Score™ is 92/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Value Rank calculated?
GF Value Rank is calculated from a company's financial statements. For Neuland Laboratories (NSE:NEULANDLAB), the current GF Value Rank is 5 as of Jul. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Neuland Laboratories (NSE:NEULANDLAB) Overvalued in 2026?

Based on GuruFocus' analysis, Neuland Laboratories stock appears to be overvalued. The current stock price of ₹19,506.00 is trading 21.5% above its estimated GF Value™ of ₹16,053.42. GuruFocus considers Neuland Laboratories to be Modestly Overvalued.

Key valuation signals for NSE:NEULANDLAB:

  • GF Value Rank: 5 (25% above median its 10-year median of 4.00)
  • GF Value™: ₹16,053.42 vs. price of ₹19,506.00 (21.5% above fair value)
  • GF Score™: 92/100 with 3 warning signs

No single metric tells the full story. See the NSE:NEULANDLAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Neuland Laboratories Business Description

Other Exchanges 524558:India
Address Road No. 82, Jubilee Hills, Plot No. 573A-III, Phoenix IVY Building, 11th Floor (5th Office Level), Hyderabad, TG, IND, 500033
Neuland Laboratories Ltd is engaged in the manufacturing and selling of bulk drugs and caters to both the domestic and international markets. It is an API contract development and manufacturing organization (CDMO), supporting biotechnology and pharmaceutical companies in the design, development, and manufacturing of complex active pharmaceutical ingredients (APIs). The company develops small molecules and peptides for clinical trials and beyond, with the capacity to scale up through every stage of the product lifecycle to commercial manufacturing. Geographically, the group derives maximum revenue from its customers in India, followed by Europe, the USA and North America, and the Rest of the world.
92GF Score

Get the complete analysis for NSE:NEULANDLAB

GF Value Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹19,506.00
Price
₹16,053.42
GF Value